Valuation : Madrigal Pharmaceuticals, Inc.

Market Cap 12.54B 10.79B 10.12B 9.26B 17.29B 1,185B 17.42B 120B 46.63B 606B 47.08B 46.05B 1,950B P/E 2026 *
-85.9x
P/E 2027 * 86.2x
Enterprise Value 12.01B 10.34B 9.7B 8.87B 16.56B 1,136B 16.69B 115B 44.68B 580B 45.11B 44.12B 1,869B EV / Sales 2026 *
7.87x
EV / Sales 2027 * 5.41x
Free-Float
94.12%
Yield 2026 *
-
Yield 2027 * -
1 day-0.79%
1 week-0.20%
Current month+0.48%
1 month+12.57%
3 months+11.16%
6 months+27.42%
Current year-6.82%
1 week 523.29
Extreme 523.29
552.08
1 month 494.9
Extreme 494.9
552.08
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 9.85
Extreme 9.85
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
17/8/26 Sell

General Counsel

-664 0.0029%
15/8/26 Free

Director

1,725 0.0075%
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%-0.20%+24.66%+193.08% 12.54B
+0.41%-2.07%+41.26%+95.40% 69.02B
-1.32%+0.58%+42.60%+89.60% 66.32B
+0.04%+4.36%-11.72%+459.54% 27.66B
-0.90%-7.65%+2.45%-15.50% 25.84B
-3.00%-2.90%+39.40%+9.41% 26.54B
-0.27%+1.30%+25.16%-17.99% 20.4B
+3.45%-13.46%+222.69%+389.50% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
+1.03%+7.00%+59.98%+160.03% 14.65B
Average -0.28%-1.26%+44.61%+189.33% 29.58B
Weighted average by Cap. -0.41%-0.81%+40.84%+150.08%

Financials

2026 *2027 *
Net sales 1.53B 1.31B 1.23B 1.13B 2.1B 144B 2.12B 14.58B 5.68B 73.73B 5.73B 5.61B 237B 2.14B 1.85B 1.73B 1.58B 2.96B 203B 2.98B 20.49B 7.98B 104B 8.05B 7.88B 334B
Net income -184M -158M -148M -136M -254M -17.38B -256M -1.76B -684M -8.88B -690M -675M -28.61B 200M 172M 161M 148M 276M 18.91B 278M 1.91B 744M 9.66B 751M 735M 31.12B
Net Debt -525M -451M -424M -387M -723M -49.58B -729M -5.01B -1.95B -25.34B -1.97B -1.93B -81.61B -943M -812M -762M -697M -1.3B -89.16B -1.31B -9.01B -3.51B -45.57B -3.54B -3.46B -147B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
03/09/26 US$542.61 -0.79% 143,455
02/09/26 US$546.93 +1.53% 202,818
01/09/26 US$538.71 -0.24% 165,754
31/08/26 US$540.03 +1.17% 134,578
28/08/26 US$533.76 -1.83% 268,664
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
542.61USD
Average target price
678.06USD
Spread / Average Target
+24.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock